1. Home
  2. NMI vs ANIX Comparison

NMI vs ANIX Comparison

Compare NMI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NMI

Nuveen Municipal Income Fund Inc.

HOLD

Current Price

$9.60

Market Cap

126.6M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.75

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMI
ANIX
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.6M
114.0M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
NMI
ANIX
Price
$9.60
$2.75
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $8.67
AVG Volume (30 Days)
32.2K
★ 352.7K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.82
EPS
★ N/A
N/A
Revenue
N/A
★ $210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.57
$2.32
52 Week High
$11.28
$5.46

Technical Indicators

Market Signals
Indicator
NMI
ANIX
Relative Strength Index (RSI) 29.60 38.62
Support Level $9.57 $2.66
Resistance Level $10.31 $3.09
Average True Range (ATR) 0.18 0.16
MACD -0.02 0.00
Stochastic Oscillator 17.05 31.25

Price Performance

Historical Comparison
NMI
ANIX

About NMI Nuveen Municipal Income Fund Inc.

Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: